Sangamo, a gene therapy pioneer, loses a financial lifeline as Pfizer drops a gene therapy program for hemophilia.

The U.S. Food and Drug Administration has approved Novo Nordisk's drug for the prevention or reduction of bleeding episodes ...

The biotech company intends to explore ways to move ahead with developing the treatment, including seeking a new collaborator ...

The FDA recently approved the treatment by Novo Nordisk for hemophilia A or B with inhibitors, designed to prevent or reduce ...

Sangamo Therapeutics (SGMO) stock plunged as Pfizer (PFE) ends collaboration on hemophilia A gene therapy. Find out the ...

After more than four decades of infusing himself with the blood clotting factor his body can’t make, Chad Stevens decided it ...

Gene therapies are revolutionizing treatment for hemophilia A and sickle cell disease; however, they are saddled with hefty ...

Columnist Jennifer Lynne knows that finding a sense of community can be challenging, but she's also learned it's worth it.

Undeterred by last year’s rejection and the recent approval of a close rival from Pfizer, Novo Nordisk has pushed its ...

Increasing Incidence of Hemostasis Disorders: Rising prevalence of hemophilia, thrombophilia, and other blood clotting disorders is driving market growth. Technological Advancements: Continuous ...

Hemophilia A ... to spontaneous and severe bleeding after injuries or surgery. Sangamo said it remains focused on advancing its other therapy for the inherited disorder Fabry disease toward ...